#Japan #Tokyo #NEDO #CaTe #Heart Rehabilitation

CaTe Inc. Receives Pivotal Support from NEDO

CaTe Inc., headquartered in Bunkyo, Tokyo, is proud to announce its acceptance into the PCA phase of the NEDO Deep Tech Startup Support Fund. This significant recognition aligns with the company’s mission to enhance cardiac rehabilitation technologies for patients suffering from heart diseases, which remain a pressing health issue globally and specifically in Japan.

Understanding the Urgency of Cardiac Rehabilitation

Heart disease ranks as the leading cause of death worldwide, with Japan witnessing alarming statistics—with approximately one-third of heart disease patients being readmitted to hospitals within a year post-discharge. Moreover, one in seven patients succumbs to the ailment shortly after initial treatment. The advent of cardiac rehabilitation programs has been shown to decrease the rates of readmission and mortality; however, participation remains woefully low—hovering around only 7% of eligible patients.

CaTe aims to tackle these pressing issues head-on by developing a remote cardiac rehabilitation system that patients can utilize from the comfort of their homes. This innovation is critical as it not only ensures better accessibility for patients but also addresses the looming issue of rising healthcare costs associated with repeat hospitalizations.

Financial Backing and Future Plans

Having successfully completed the STS phase of the 2023 NEDO DTSU project with a funding of approximately 1.9 billion yen, CaTe now looks forward to securing a maximum government grant of 960 million yen under the PCA phase. Alongside planned Series B fundraising of 1.73 billion yen, the company aims to utilize a total of 3.5 billion yen for further extensive research and development of its groundbreaking cardiac rehabilitation programs. This funding will facilitate clinical trials and accelerate the international deployment of these life-saving technologies.

The NEDO DTSU project endeavors to meld innovative technology with the complexities of long-term research and substantial funding to develop viable solutions to significant socio-economic issues. With support spanning three distinct phases—STS, PCA, and DMP—NEDO aims to guide startups through the rigorous journey of bringing cutting-edge technologies to market.

Leadership Vision

CaTe’s CEO Kazuhisa Terashima expressed deep gratitude for being selected for the NEDO DTSU initiative, which empowers the company’s vision to provide comprehensive cardiac rehabilitation that remains underrepresented in current medical practices. Furthermore, CFO Tomoki Miyazaki emphasized the company’s commitment to leveraging both the NEDO funds and Series B investments to hasten the validation trials and promote a broader global outreach.

Through a united effort, CaTe envisions a society where every patient dealing with heart conditions can receive effective and secure rehabilitation services that are not bound by time or location. The company looks forward to continuing its productive partnerships with healthcare providers, stakeholders, and investors to turn this vision into reality.

Company Background

Founded on March 18, 2020, CaTe Inc. is certified under the second type of medical device manufacturing and sales. With its rapid advancements and innovative vision, the company is strategically positioned to change the landscape of cardiac rehabilitation, paving the way for a healthier society.

Headquarters: 5F Sky Vision Bldg, 5-25-13 Hongo, Bunkyo, Tokyo, 113-0033, Japan
Nagoya Office: 1-2-32 Tsuruma, Showa, Nagoya, 466-0064, Japan
Website: CaTe Inc.

By pioneering such transformative solutions, CaTe is setting the stage for a revolutionary approach to heart disease recovery, contributing to both personal health advancements and broader public health improvements.